Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | estrogen receptor 1 | Starlite/ChEMBL | References |
Homo sapiens | estrogen receptor 2 (ER beta) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | estrogen receptor 2 (ER beta) | 495 aa | 418 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.0196 | 0 | 0.5 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0594 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0399 | 0.5096 | 0.4103 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0431 | 0.5902 | 0.5 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.0196 | 0 | 0.5 |
Leishmania major | DNA topoisomerase ii | 0.0534 | 0.85 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0534 | 0.85 | 1 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0594 | 1 | 0.5 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0534 | 0.85 | 1 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0594 | 1 | 1 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.0196 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0399 | 0.5096 | 0.4103 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0594 | 1 | 0.5 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0431 | 0.5902 | 0.5 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0594 | 1 | 1 |
Schistosoma mansoni | DNA topoisomerase II | 0.0594 | 1 | 0.5 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0594 | 1 | 0.5 |
Giardia lamblia | DNA topoisomerase II | 0.0568 | 0.9342 | 0.5 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0322 | 0.3184 | 1 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0594 | 1 | 0.5 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0594 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.0196 | 0 | 0.5 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0594 | 1 | 0.5 |
Brugia malayi | Probable DNA topoisomerase II | 0.0594 | 1 | 0.5 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0534 | 0.85 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0431 | 0.5902 | 0.5 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0534 | 0.85 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 105 nM | Inhibitory concentration against human ER beta expressed in E. coli was determined using [3H]-17-beta-estradiol as radio ligand | ChEMBL. | 15456246 |
IC50 (binding) | = 105 nM | Inhibitory concentration against human ER beta expressed in E. coli was determined using [3H]-17-beta-estradiol as radio ligand | ChEMBL. | 15456246 |
IC50 (binding) | = 105 nM | Binding affinity to ERbeta | ChEMBL. | 17459530 |
IC50 (binding) | = 2410 nM | Inhibitory concentration against human ER alpha expressed in E. coli was determined using [3H]-17-beta-estradiol as radio ligand | ChEMBL. | 15456246 |
IC50 (binding) | = 2410 nM | Inhibitory concentration against human ER alpha expressed in E. coli was determined using [3H]-17-beta-estradiol as radio ligand | ChEMBL. | 15456246 |
Selectivity (binding) | = 20 | Selectivity fold for estrogen receptor beta over estrogen receptor alpha | ChEMBL. | 15456246 |
Selectivity (binding) | = 20 | Selectivity fold for estrogen receptor beta over estrogen receptor alpha | ChEMBL. | 15456246 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.